<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173611</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-121</org_study_id>
    <nct_id>NCT04173611</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers</brief_title>
  <official_title>Phase 1, Randomized, Double-Blind, Active and Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To assess the safety and tolerability of EXPAREL® administered as a single&#xD;
      intrathecal injection in healthy volunteers&#xD;
&#xD;
      Secondary objective: To characterize the pharmacokinetic (PK) and pharmacodynamic (PD)&#xD;
      profile of EXPAREL® administered as a single intrathecal injection in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase-1, single center, randomized, double-blind, active and placebo-controlled&#xD;
      study in approximately 40 healthy adult subjects.&#xD;
&#xD;
      On Day 1, eligible subjects will be randomized in blocks of 5, in a ratio of 3:1:1 to receive&#xD;
      EXPAREL® or bupivacaine or placebo (saline) injection, respectively. Starting with treatment&#xD;
      Cohort 1, healthy volunteers will be randomized to the 3 treatment arms within cohorts. Each&#xD;
      cohort will consist of 10 subjects (6 EXPAREL®, 2 bupivacaine and 2 placebo). In each cohort,&#xD;
      all 10 subjects in each cohort will receive cerebrospinal fluid (CSF) taps. Within the&#xD;
      EXPAREL® arm, subjects will be randomized 2:1 with 4 subjects undergoing CSF tap and 2&#xD;
      subjects not undergoing CSF tap in each cohort. Subjects who are not undergoing CSF tap, will&#xD;
      still be injected with needles without draw of CSF to prevent subject bias. Such a&#xD;
      randomization will allow for characterization of the complete pharmacodynamics profile of the&#xD;
      drug without risk of drug removal in the CSF. For those subjects randomized to the EXPAREL®&#xD;
      arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1 mL (13.3 mg) for&#xD;
      Cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a&#xD;
      maximum of 4 mL (53.2 mg). The decision to proceed to the next cohort will be made following&#xD;
      a full review of the safety, PK, and PD (sensory and motor) data from current completed&#xD;
      cohort(s). All subjects will remain in the EPRU for 5 days after drug administration and will&#xD;
      be discharged on Day 6. Subjects will be instructed to return for a follow up visit on Day 9.&#xD;
      Adverse events (AEs) and serious adverse events (SAEs) will be recorded from the time of&#xD;
      consent through 30 days after drug administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for strategic and administrative reasons&#xD;
  </why_stopped>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Actual">December 7, 2020</completion_date>
  <primary_completion_date type="Actual">December 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The decision to proceed to each next cohort will be made following a full review of the safety, PK, and PD data from the previous completed cohort(s).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Each of the cohorts will be masked as to proceed to subsequent next dose escalation cohort.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-versus-time curve</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) and time of Cmax (Tmax).</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent terminal elimination half-life (t1/2el)</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vd)</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacokinetic endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs (TEAEs) through Day 9</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have any of neurological events</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Average time to onset of sensory block and motor block</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacodynamic Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Average duration of sensory block and motor block</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Pharmacodynamic Endpoint</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>EXPAREL®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In each cohort, subjects randomized to the bupivacaine arm will receive 15mg of plain bupivacaine HCL (the equivalent of 13.3mg bupivacaine base) providing a 1:1 reference to the starting dose level chosen for EXPAREL®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the placebo arm will receive normal saline intrathecal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL</intervention_name>
    <description>Injection into the Intrathecal space.</description>
    <arm_group_label>EXPAREL®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Injection into the Intrathecal space.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>0.5% Bupivacaine HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection into the Intrathecal space.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female volunteers ages ≥18 and ≤50 years old.&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) physical status 1.&#xD;
&#xD;
          3. Able to provide informed consent, adhere to the study schedule, and complete all study&#xD;
             assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study&#xD;
             medications for which an alternative is not named in the protocol (eg, amide-type&#xD;
             local anesthetics, opioids, bupivacaine, non-steroidal anti-inflammatory drugs&#xD;
             [NSAIDs], spinal anesthesia).&#xD;
&#xD;
          2. Impaired renal or hepatic function (eg, serum creatinine level &gt;2 mg/dL [176.8&#xD;
             μmol/L], blood urea nitrogen level &gt;50 mg/dL [17.9 mmol/L], serum aspartate&#xD;
             aminotransferase [AST] level &gt;1.5 times the upper limit of normal [ULN], or serum&#xD;
             alanine aminotransferase [ALT] level &gt;1.5 times the ULN).&#xD;
&#xD;
          3. Subjects at an increased risk for bleeding or who have a coagulation disorder (defined&#xD;
             as platelet count less than 80,000 × 103/mm3).&#xD;
&#xD;
          4. Concurrent painful physical condition that may require analgesic treatment (such as&#xD;
             long-term, consistent use of opioids) in the post dosing period for pain and which may&#xD;
             confound the post dosing assessments.&#xD;
&#xD;
          5. Women of childbearing potential must have a documented negative pregnancy test at&#xD;
             screening and must be confirmed on the day of drug administration. If postmenopausal,&#xD;
             must have a documented Follicle Stimulating Hormone (FSH) test confirming menopause at&#xD;
             screening.&#xD;
&#xD;
          6. Currently pregnant, nursing, or planning to become pregnant during the study or within&#xD;
             30 days after completion of the study.&#xD;
&#xD;
          7. Positive serology test result for Human Immunodeficiency Virus (HIV), Hepatitis B&#xD;
             virus, or Hepatitis C virus.&#xD;
&#xD;
          8. Clinically significant abnormal ECG that in the opinion of the investigator would&#xD;
             preclude the subject from participation in the study.&#xD;
&#xD;
          9. Previous participation in a Pacira study.&#xD;
&#xD;
         10. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
&#xD;
         11. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald C Manning, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

